MedTrace Logo

Brown Seaweeds Effect on Glucose Tolerance and Appetite Response

NCT02608372 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-08-27

No results posted yet for this study

Summary

The project is a randomized, 3-way, blinded crossover trial in which 20 healthy, fasted participants consume meals with 30 g of a linear corn starch and 5 g of one of the seaweeds, Laminara digitata or Undaria pinnatifida or a pea protein control. The primary aim is to investigate whether the brown seaweeds affect the postprandial glucose Area Under the Curve (AUC). Stomach emptying, insulin, C-peptide, appetite-regulating hormones (oxyntomodulin, glucagon, GLP-1 and PYY), and specific metabolites from the seaweeds in the urine and plasma as well as subjective satiety are also analyzed.

Conditions

  • High Blood Glucose

Interventions

OTHER

LD

Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.

OTHER

UP

Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.

OTHER

CTR

Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.

Sponsors & Collaborators

  • Ministry of Education, Malaysia

    collaborator OTHER_GOV

  • Universiti Malaysia Pahang

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Lars O Dragsted, PhD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-07-31
Completion
2015-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608372 on ClinicalTrials.gov